Zoetis Inc. (NYSE:ZTS – Get Rating) shares hit a new 52-week low on Tuesday . The stock traded as low as $153.20 and last traded at $153.20, with a volume of 3722 shares changing hands. The stock had previously closed at $157.19.
Analyst Ratings Changes
Several brokerages have recently weighed in on ZTS. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. Stifel Nicolaus decreased their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Piper Sandler initiated coverage on shares of Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price objective on the stock. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group decreased their price objective on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $224.00.
Zoetis Price Performance
The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 1.14. The business’s 50-day simple moving average is $168.03 and its 200 day simple moving average is $173.80. The firm has a market capitalization of $70.80 billion, a P/E ratio of 34.29, a PEG ratio of 2.74 and a beta of 0.77.
Insider Buying and Selling at Zoetis
In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at $4,145,225. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. Insiders have sold 16,501 shares of company stock worth $2,949,073 over the last ninety days. Insiders own 0.12% of the company’s stock.
Institutional Trading of Zoetis
Institutional investors have recently made changes to their positions in the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the period. American National Bank lifted its stake in Zoetis by 469.2% in the second quarter. American National Bank now owns 148 shares of the company’s stock worth $25,000 after acquiring an additional 122 shares during the period. Financial Management Professionals Inc. lifted its stake in Zoetis by 117.4% in the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after acquiring an additional 81 shares during the period. Mystic Asset Management Inc. purchased a new stake in Zoetis in the fourth quarter worth $37,000. Finally, Worth Asset Management LLC purchased a new stake in Zoetis in the first quarter worth $26,000. Hedge funds and other institutional investors own 91.05% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.